Platelet hyperactivation in maintained human growth hormone HGH-deficient childhood patients after therapy withdrawal as a putative earlier marker of increased cardiovascular risk.
Reis F - J Clin Endocrinol Metab - 01-JAN-2005; 90(1): 98-105
From NIH/NLM MEDLINE
NLM Citation ID:
15494463 (PubMed)
Full Source Title:
Journal of Clinical Endocrinology and Metabolism
Publication Type:
Journal Article
Language:
English
Author Affiliation:
Unit of Therapeutics, Botanic Department, Science and Technology Faculty, Coimbra University, 3004-504 Coimbra, Portugal.
Authors:
Reis F; Campos MV; Bastos M; Almeida L; Lourenço M; Ferrer-Antunes CA; Palmeiro A; Santos-Dias JD; Mesquita JF; Carvalheiro M; Teixeira F
Abstract:
HGH deficiency (HGHD) is associated with a higher risk of vascular disease, whose pathophysiological mechanisms remains not yet fully elucidated. This study aimed to assess the main cardiovascular risk indexes, plasma catecholamines content, and the platelet function in childhood-onset HGHD patients.Some of the main clinical examinations related with cardiovascular risk, plasma catecholamines content, as well as platelet intracellular free calcium concentration ([Ca(2+)](i)), whole-blood aggregation, and morphology were evaluated in childhood-onset HGHD patients treated with HGH for a variable period and off HGH therapy for at least 2 yr before entry into study and in sex-, age-, and body mass index-matched control groups. Among the patients, group 1 (HGHD-1) has recovered HGH levels after withdrawal, whereas group 2 (HGHD-2) has remained HGH deficient.Minor differences on the cardiovascular risk indexes were observed between the groups. Plasma catecholamine concentrations in the HGHD groups did not statistically differ from the control group, but higher adrenaline content was observed in the HGHD-2 group when compared with the HGHD-1 one. Basal and thrombin-evoked [Ca(2+)](i) and platelet aggregation were identical between the GHD-1 group and the matched control. However, the GHD-2 group has increased thrombin-evoked [Ca(2+)](i) (297.0 +/- 15.7 Deltanmol/liter; P < 0.01), collagen, and ADP-induced platelet aggregation (33.3 +/- 4.3 and 12.5 +/- 2.1 Omega, respectively; P < 0.05) vs. the control-2 group (Delta[Ca(2+)](i): 102.1 +/- 13.6 Deltanmol/liter; aggregation: 19.6 +/- 2.9 and 6.2 +/- 0.8 Omega). The platelet hyperreactivity state in the HGHD-2 was reinforced by morphologic studies of electron microscopy.In conclusion, there were minor differences between the GHD-1 group and the controls, which might be due to the recovery of HGH levels after therapy withdrawal. However, the maintained HGHD group, despite minor cardiovascular risk index differences, has increased [Ca(2+)](i) and aggregation, which could indicate a hyperactivation state that might be viewed as an earlier marker of cardiovascular disturbances.
Major Subjects:
- Cardiovascular Diseases / * etiology
- Human Growth Hormone / * deficiency
- Platelet Activation
Additional Subjects:
- Adult
- Biological Markers
- Blood Platelets / chemistry / ultrastructure
- Calcium / blood
- Catecholamines / blood
- Female
- Humans
- Lipoproteins, HDL Cholesterol / blood
- Lipoproteins, LDL Cholesterol / blood
- Male
- Platelet Aggregation
- Risk
Chemical Compound Name:
(Biological Markers); (Catecholamines); (Lipoproteins, HDL Cholesterol); (Lipoproteins, LDL Cholesterol); 12629-01-5(Human Growth Hormone); 7440-70-2(Calcium)